LYFE Capital

– ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital.
– Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and Lucion Capital, participated in the new round.
– ABclonal Biotechnology, parent company of Massachusetts-based life science research and diagnostic reagents manufacturer, ABclonal Technology, will use the additional funding to accelerate the company’s research and development pipeline for in vitro diagnostic raw materials and rapidly expand production capabilities of its research reagent products and services.
– ABclonal is also currently in talks to acquire a contract research organization focused on single-cell-based monoclonal antibody development. This will be the company’s first step toward using the $92.

– Sciwind biosciences secured US$37m series B financing.
– The financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.
– Sciwind focuses on research and development of innovative biologics in the therapeutic area of chronic metabolic and immunological diseases and has driven multiple projects into clinical trials.
– Two more IND applications are expected to be filed in 2021 including an oral formulation of a highly active GLP-1 analogue.